Hoth Therapeutics (HOTH) announced its collaboration with OnTargetx R&D to advance research for its cancer-fighting therapeutic, HT-KIT. The study focuses on: development and optimization of staining methods for markers; processing and qualitative evaluation of tissue samples by a board-certified pathologist to determine the presence of markers; and comprehensive reporting and insights to support the continued development of HT-KIT.
"This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments," said Robb Knie, CEO at Hoth Therapeutics.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.